Elanco/$ELAN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Elanco

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Ticker

$ELAN

Primary listing

NYSE

Industry

Pharmaceuticals

Employees

9,225

ISIN

US28414H1032

Elanco Metrics

BasicAdvanced
$7.4B
19.96
$0.75
1.68
-

What the Analysts think about Elanco

Analyst ratings (Buy, Hold, Sell) for Elanco stock.

Bulls say / Bears say

Stifel raised Elanco's price target to $17, citing gains in parasiticide market share and strong performance of products like Credelio Quattro, Advantage, and Seresto. (Investing.com)
Elanco's restructuring plan, including the divestiture of its aqua business, is expected to result in annualized net savings of $30 to $35 million, allowing the company to focus on higher-growth areas. (TradingView)
The company received multiple regulatory approvals for new products, including Bovaer, Zenrelia, Credelio Quattro, and Experior, which are anticipated to drive future growth. (TradingView)
Elanco is under investigation for potential securities fraud related to misleading statements about FDA approvals, leading to a significant stock price decline. (GuruFocus)
Barclays issued a pessimistic forecast for Elanco's stock price, reflecting concerns about the company's future performance. (Techdows)
Elanco faces operational risks from manufacturing problems and capacity imbalances, which can lead to product launch delays, inventory shortages, and increased costs. (TradingView)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Elanco Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Elanco Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ELAN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs